Nkarta reports third quarter 2020 financial results

South san francisco, calif., nov. 12, 2020 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a clinical-stage biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today reported financial results for the third quarter ended september 30, 2020, and highlighted recent corporate accomplishments.
NKTX Ratings Summary
NKTX Quant Ranking